Cart
sales@molnova.com
Gallein
CAS No. 2103-64-2
Gallein( 4,5-Dihydroxyfluorescein, AI3-63042, Gallein, Pyrogallolphthalein )
Catalog No. M18231 CAS No. 2103-64-2
Gallein is a small molecule inhibitor of Gβγ activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 33 | In Stock |
|
| 5MG | 29 | In Stock |
|
| 10MG | 42 | In Stock |
|
| 25MG | 61 | In Stock |
|
| 50MG | 88 | In Stock |
|
| 100MG | 114 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGallein
-
NoteResearch use only, not for human use.
-
Brief DescriptionGallein is a small molecule inhibitor of Gβγ activity.
-
DescriptionGallein is a Gβγ subunit signalling inhibitor which has been shown to inhibit metastatic spread of tumour cells expressing OR51E2 and exposed to its odorant ligand.
-
In Vitro——
-
In Vivo——
-
Synonyms4,5-Dihydroxyfluorescein, AI3-63042, Gallein, Pyrogallolphthalein
-
PathwayOthers
-
TargetAntioxidant
-
RecptorGβγ
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2103-64-2
-
Formula Weight364.31
-
Molecular FormulaC20H12O7
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 33.33 mg/mL (91.49 mM)
-
SMILESc1ccc2c(c1)C(=O)OC12c2c(c(c(cc2)O)O)Oc2c1ccc(c2O)O
-
Chemical Name3',4',5',6'-Tetrahydroxyspiro(isobenzofuran-1(3H),9'-(9H)xanthene)-3-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. White SM, et al. Mol Pharmacol. 2014 Oct;86(4):369-77.
molnova catalog
related products
-
Isocurcumenol
Isocurcumenol inhibits 5α-reductase which converts testosterone to dihydrotestosterone (DHT).
-
Scutellarin
Scutellarin, an active flavone isolated from Scutellaria baicalensis, can inhibit RANKL-mediated MAPK and NF-κB signaling pathway in osteoclasts, and down-regulate the STAT3/Girdin/Akt signaling in HCC cells.
-
Dimethylacrylshikoni...
Dimethylacrylshikonin is a promising agent for developing an improved strategy for radiotherapy against tumors.
